278 related articles for article (PubMed ID: 15963241)
1. Anti-proliferative effects, cell cycle G2/M phase arrest and blocking of chromosome segregation by probimane and MST-16 in human tumor cell lines.
Lu DY; Huang M; Xu CH; Yang WY; Hu CX; Lin LP; Tong LJ; Li MH; Lu W; Zhang XW; Ding J
BMC Pharmacol; 2005 Jun; 5():11. PubMed ID: 15963241
[TBL] [Abstract][Full Text] [Related]
2. Medicinal chemistry of probimane and MST-16: comparison of anticancer effects between bisdioxopiperazines.
Lu DY; Huang M; Xu CH; Zhu H; Xu B; Ding J
Med Chem; 2006 Jul; 2(4):369-75. PubMed ID: 16848748
[TBL] [Abstract][Full Text] [Related]
3. Anticancer activities and mechanisms of bisdioxopiperazine compounds probimane and MST-16.
Lu DY; Lu TR
Anticancer Agents Med Chem; 2010 Jan; 10(1):78-91. PubMed ID: 19845502
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of two bisdioxopiperazines against two experimental lung cancer models in vivo.
Lu DY; Xu B; Ding J
BMC Pharmacol; 2004 Dec; 4():32. PubMed ID: 15617579
[TBL] [Abstract][Full Text] [Related]
5. Antimetastatic activities and mechanisms of bisdioxopiperazine compounds.
Lu DY; Lu TR
Anticancer Agents Med Chem; 2010 Sep; 10(7):564-70. PubMed ID: 20950258
[TBL] [Abstract][Full Text] [Related]
6. MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy.
Yoshida M; Maehara Y; Sugimachi K
Clin Cancer Res; 1999 Dec; 5(12):4295-300. PubMed ID: 10632373
[TBL] [Abstract][Full Text] [Related]
7. Cell biological manifestations of bisdioxopiperazines treatment of human tumor cell lines in culture.
Lu DY; Lu DR; Ding J
Anticancer Agents Med Chem; 2010 Nov; 10(9):657-60. PubMed ID: 21235436
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
[TBL] [Abstract][Full Text] [Related]
9. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
10. Individual and interactive effects of apigenin analogs on G2/M cell-cycle arrest in human colon carcinoma cell lines.
Wang W; VanAlstyne PC; Irons KA; Chen S; Stewart JW; Birt DF
Nutr Cancer; 2004; 48(1):106-14. PubMed ID: 15203384
[TBL] [Abstract][Full Text] [Related]
11. MONCPT exerts anti-cancer activities via inducing G2/M arrest and apoptosis in human bladder cancer.
Zhu Y; Jiang H; Zhang C; He QJ; Yang B; Li LJ; Zhu H
Pharmazie; 2009 Dec; 64(12):823-8. PubMed ID: 20095141
[TBL] [Abstract][Full Text] [Related]
12. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
13. Effects of the L isomer (+)-1,2-bis(3,5-dioxopiperazine-1-yl)propane on cell survival and cell cycle progression of cultured mammalian cells.
Traganos F; Darzynkiewicz Z; Melamed MR
Cancer Res; 1981 Nov; 41(11 Pt 1):4566-76. PubMed ID: 6171341
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action.
van Hille B; Etiévant C; Barret JM; Kruczynski A; Hill BT
Anticancer Drugs; 2000 Nov; 11(10):829-41. PubMed ID: 11142691
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effect of probimane on anticancer cytotoxicity of doxorubicin in vitro.
Zhang Y; Ye QX; Liu J; Zhang ZY; Zhang TM
Zhongguo Yao Li Xue Bao; 1994 Jan; 15(1):56-9. PubMed ID: 8010087
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane; ADR-529] and ICRF-159 (Razoxane).
Gorbsky GJ
Cancer Res; 1994 Feb; 54(4):1042-8. PubMed ID: 8313360
[TBL] [Abstract][Full Text] [Related]
17. G2/M cell cycle arrest and induction of apoptosis by a stilbenoid, 3,4,5-trimethoxy-4'-bromo-cis-stilbene, in human lung cancer cells.
Lee EJ; Min HY; Joo Park H; Chung HJ; Kim S; Nam Han Y; Lee SK
Life Sci; 2004 Oct; 75(23):2829-39. PubMed ID: 15464834
[TBL] [Abstract][Full Text] [Related]
18. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
19. Selective induction of G2/M arrest and apoptosis in HL-60 by a potent anticancer agent, HMJ-38.
Yang JS; Hour MJ; Kuo SC; Huang LJ; Lee MR
Anticancer Res; 2004; 24(3a):1769-78. PubMed ID: 15274354
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors.
Ishida R; Miki T; Narita T; Yui R; Sato M; Utsumi KR; Tanabe K; Andoh T
Cancer Res; 1991 Sep; 51(18):4909-16. PubMed ID: 1654205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
